Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Biochim Biophys Acta. 2011 Oct 29;1823(3):742–755. doi: 10.1016/j.bbamcr.2011.10.008

Table 1.

Hsp90 inhibitors in clinical evaluation

Inhibitor Company Structure Class Route Phase
1. Tanespimycin (17-AAG, KOS-953) Kosan Biosciences/Bristol-Myers-Squibb graphic file with name nihms340577t1.jpg GM IV III
2. Alvespimycin (17-DMAG) Kosan Biosciences/Bristol-Myers-Squibb graphic file with name nihms340577t2.jpg GM IV
Oral		 I
3. Retaspimycin (IPI-504) Infinity Pharmaceuticals graphic file with name nihms340577t3.jpg GM IV III
4. IPI-493 Infinity Pharmaceuticals graphic file with name nihms340577t4.jpg GM Oral I
5. CNF2024/BIIB 021 Biogen Idec graphic file with name nihms340577t5.jpg Purine Oral II
6. MPC-3100 Myriad Pharmaceuticals/Myrexis graphic file with name nihms340577t6.jpg Purine Oral I
7. Debio 0932 (CUDC-305) DebioPharm graphic file with name nihms340577t7.jpg Purine-like Oral I
8. PU-H71 Samus Therapeutics graphic file with name nihms340577t8.jpg Purine IV I
9. Ganetespib (STA-9090) Synta Pharmaceuticals Not reported Resorcinol - Triazole IV II
10. NVP-AUY922 (VER-52269) Novartis graphic file with name nihms340577t9.jpg Resorcinol - Isoxazole IV II
11. HSP990 Novartis Not reported but claimed as a follow up compound to NVP-AUY922 not reported Oral I
12. KW-2478 Kyowa Hakko Kirin Pharma graphic file with name nihms340577t10.jpg Resorcinol IV I
13. AT13387 Astex graphic file with name nihms340577t11.jpg Resorcinol IV
Oral		 I
14. SNX-5422 Serenex/Pfizer graphic file with name nihms340577t12.jpg Indazol-4-one Oral I
15. DS-2248 Daiichi Sankyo Inc Not reported not reported Oral I
16. XL888 Exelixis Not reported not reported Oral I